X

Drug Profile

Aceclidine/tropicamide - LENZ Therapeutics

Alternative Names: PRX 100; Tropicamide/aceclidine

Latest Information Update: 25 Jun 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Presbyopia Therapies
Developer LENZ Therapeutics
Class Azabicyclo compounds; Eye disorder therapies; Pyridines
Mechanism of Action Adrenergic receptor agonists; Cholinergic receptor agonists; Muscarinic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Presbyopia

Most Recent Events

17 Jun 2021 Presbyopia Therapies is now called LENZ Therapeutics
17 Jun 2021 LENZ Therapeutics announces intention to submit NDA to the US FDA for Presbyopia
30 Jul 2018 Efficacy and safety data from a phase IIb trial in Presbyopia released by Presbyopia Therapies (NCT03201562)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com